

This material is an English translation of the press release announced on October 7, 2020 in Japanese, and the Japanese release is given priority about the content and the interpretation.

October 7, 2020

**Notification of the commencement of the Phase III clinical study of HP-5070
in Japan (primary palmar hyperhidrosis treatment drug)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; President and CEO: Kazuhide Nakatomi, hereinafter referred to as “Hisamitsu Pharmaceutical”) announces that it has commenced of the Phase III clinical study in Japan for the primary palmar hyperhidrosis treatment drug (Development code: HP-5070, generic name: oxybutynin hydrochloride, hereinafter referred to as “the investigational product”).

In the Phase III clinical study, the efficacy and safety of administration of the investigational product will be compared with a placebo in patients with primary palmar hyperhidrosis.

The investigational product is a topical formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. Hisamitsu pharmaceutical expects it to be a new option for the treatment of primary palmar hyperhidrosis.

In the future, Hisamitsu pharmaceutical aims to apply for manufacturing and marketing approval during FY2022.